RU2017143849A3 - - Google Patents

Download PDF

Info

Publication number
RU2017143849A3
RU2017143849A3 RU2017143849A RU2017143849A RU2017143849A3 RU 2017143849 A3 RU2017143849 A3 RU 2017143849A3 RU 2017143849 A RU2017143849 A RU 2017143849A RU 2017143849 A RU2017143849 A RU 2017143849A RU 2017143849 A3 RU2017143849 A3 RU 2017143849A3
Authority
RU
Russia
Application number
RU2017143849A
Other versions
RU2017143849A (ru
RU2716595C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017143849A publication Critical patent/RU2017143849A/ru
Publication of RU2017143849A3 publication Critical patent/RU2017143849A3/ru
Application granted granted Critical
Publication of RU2716595C2 publication Critical patent/RU2716595C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
RU2017143849A 2015-06-30 2016-06-20 Твёрдый состав для перорального применения, содержащий иринотекан, и способ его получения RU2716595C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150093413A KR102293907B1 (ko) 2015-06-30 2015-06-30 이리노테칸 함유 경구용 고형제제 및 그 제조방법
KR10-2015-0093413 2015-06-30
PCT/KR2016/006513 WO2017003120A1 (en) 2015-06-30 2016-06-20 Oral solid formulation containing irinotecan and method of preparing the same

Publications (3)

Publication Number Publication Date
RU2017143849A RU2017143849A (ru) 2019-08-01
RU2017143849A3 true RU2017143849A3 (ru) 2019-09-25
RU2716595C2 RU2716595C2 (ru) 2020-03-13

Family

ID=57608859

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017143849A RU2716595C2 (ru) 2015-06-30 2016-06-20 Твёрдый состав для перорального применения, содержащий иринотекан, и способ его получения

Country Status (31)

Country Link
US (2) US11090299B2 (ru)
EP (1) EP3300483B1 (ru)
JP (2) JP6835746B2 (ru)
KR (2) KR102293907B1 (ru)
CN (1) CN107949375B (ru)
AR (1) AR105203A1 (ru)
AU (2) AU2016286804B2 (ru)
BR (1) BR112017028468B1 (ru)
CA (1) CA2988079C (ru)
CL (1) CL2017003437A1 (ru)
CO (1) CO2017013317A2 (ru)
CR (1) CR20170604A (ru)
DO (1) DOP2017000307A (ru)
EC (1) ECSP17085443A (ru)
ES (1) ES2930663T3 (ru)
GT (1) GT201700280A (ru)
HK (1) HK1246656A1 (ru)
IL (1) IL256278B (ru)
JO (1) JO3683B1 (ru)
MX (2) MX2017014994A (ru)
MY (1) MY191297A (ru)
PE (1) PE20181040A1 (ru)
PH (1) PH12017502376B1 (ru)
RU (1) RU2716595C2 (ru)
SA (1) SA517390602B1 (ru)
SG (1) SG10201913274VA (ru)
SV (1) SV2017005603A (ru)
TW (2) TWI750125B (ru)
UY (1) UY36761A (ru)
WO (1) WO2017003120A1 (ru)
ZA (1) ZA201708429B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
KR102444073B1 (ko) * 2020-01-06 2022-09-16 (주)휴온스 안정성이 향상된 메틸에르고메트린말레산염 함유 약제학적 제제 및 이의 제조방법
KR20220006776A (ko) * 2020-07-09 2022-01-18 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법
JP2023536341A (ja) * 2020-08-06 2023-08-24 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む経口用固形製剤及びその製造方法
KR20230104151A (ko) 2020-10-07 2023-07-07 아테넥스, 인크. 아세트아미도-페닐테트라졸 유도체 및 그의 사용 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JP2002518332A (ja) 1998-06-18 2002-06-25 ジョージワシントン大学 副作用低減を伴う癌治療のためのカンプトテシン化合物の投与方法
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
JP2002154963A (ja) 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
MXPA04008484A (es) * 2002-03-01 2004-12-06 Pharmacia Italia Spa Forma polimorfica cristalina de clorhidrato de irinotecano.
US20060030578A1 (en) 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
JP4245384B2 (ja) * 2003-03-18 2009-03-25 株式会社ヤクルト本社 カンプトテシン類含有医薬組成物
US20050208146A1 (en) * 2003-10-30 2005-09-22 Pfizer Inc Novel dosage and administration method for oral camptosar
WO2006038526A1 (ja) * 2004-10-01 2006-04-13 Kabushiki Kaisha Yakult Honsha イリノテカン酸付加塩
RU2382648C2 (ru) 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
MX2007014782A (es) 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
CN101283983A (zh) * 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物
US7880591B2 (en) 2008-02-01 2011-02-01 Apple Inc. Consumer abuse detection system and method
EP2153821A1 (en) 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
CN102617584B (zh) 2012-03-14 2013-10-16 海南锦瑞制药股份有限公司 一种盐酸伊立替康化合物及其药物组合物
AU2013352369B2 (en) 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
KR102537085B1 (ko) * 2014-01-17 2023-05-25 옹코랄 파르마 에이피에스 암의 치료를 위한 이리노테칸의 고형 경구 투여형
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법

Also Published As

Publication number Publication date
PH12017502376A1 (en) 2018-06-25
ECSP17085443A (es) 2018-01-31
KR102293907B1 (ko) 2021-08-26
PH12017502376B1 (en) 2018-06-25
JP2018519279A (ja) 2018-07-19
JP2021070705A (ja) 2021-05-06
CN107949375B (zh) 2023-04-21
ZA201708429B (en) 2019-06-26
CR20170604A (es) 2018-04-27
DOP2017000307A (es) 2018-03-15
AU2021204259A1 (en) 2021-07-22
IL256278A (en) 2018-02-28
RU2017143849A (ru) 2019-08-01
ES2930663T3 (es) 2022-12-20
CL2017003437A1 (es) 2018-06-22
EP3300483A4 (en) 2018-12-12
US20180153878A1 (en) 2018-06-07
US20210330666A1 (en) 2021-10-28
TWI750125B (zh) 2021-12-21
CA2988079A1 (en) 2017-01-05
KR20170003143A (ko) 2017-01-09
CA2988079C (en) 2023-09-26
US11090299B2 (en) 2021-08-17
BR112017028468A2 (pt) 2018-08-28
TW202137985A (zh) 2021-10-16
CN107949375A (zh) 2018-04-20
JP6835746B2 (ja) 2021-02-24
GT201700280A (es) 2019-10-10
BR112017028468B1 (pt) 2023-03-28
UY36761A (es) 2016-12-30
EP3300483B1 (en) 2022-11-09
RU2716595C2 (ru) 2020-03-13
SA517390602B1 (ar) 2022-11-09
SG10201913274VA (en) 2020-03-30
AR105203A1 (es) 2017-09-13
WO2017003120A1 (en) 2017-01-05
PE20181040A1 (es) 2018-07-03
EP3300483A1 (en) 2018-04-04
KR20210106946A (ko) 2021-08-31
IL256278B (en) 2020-11-30
AU2016286804A1 (en) 2017-11-30
CO2017013317A2 (es) 2018-03-28
MX2017014994A (es) 2018-08-15
NZ737238A (en) 2024-03-22
MX2021004439A (es) 2021-05-27
JO3683B1 (ar) 2020-08-27
HK1246656A1 (zh) 2018-09-14
TW201713339A (zh) 2017-04-16
KR102317664B1 (ko) 2021-10-26
SV2017005603A (es) 2018-03-12
AU2016286804B2 (en) 2021-03-25
MY191297A (en) 2022-06-14

Similar Documents

Publication Publication Date Title
RU2017143849A3 (ru)
BR112017026499A2 (ru)
BE2015C047I2 (ru)
BE2015C044I2 (ru)
BR112016020750A8 (ru)
BR0009761B1 (ru)
BR0005085B1 (ru)
CN303070784S (ru)
BR0009649B1 (ru)
BR0000126B1 (ru)
CN303069007S (ru)
CN303068603S (ru)
BR8103686Y1 (ru)
CN303070853S (ru)
CN303070879S (ru)
CN303072173S (ru)
BR0308527B1 (ru)
BR0303112B1 (ru)
BR0105269B1 (ru)
BR0010150B1 (ru)
BR0009994B1 (ru)
BR0009942B1 (ru)
BR0009349B1 (ru)
BR0008158B1 (ru)
BR0009757B1 (ru)